Formulation and evaluation of anti-asthmatic drug montelukast in mucoadhesive buccal patches

Abstract

To increase bioavailability of montelukast sodium (MS), mucoadhesive buccal patches are used[1]. Problems such as high first pass metabolisms and drug degradation in the gastrointestinal tract can be circumvented by administrating the drug buccal routes[2]. Moreover, buccal drug delivery offers safe and easy method of drugs utilization, as drug absorption can be promptly terminated in case of toxicity by removing buccal dosage form from buccal cavity[3]. The buccal region offers an attractive route of administration for systemic drug delivery. Pharmaceutical aspects of mucoadhesion have been the subject of great interest during recent years, because it provides the possibility of avoiding either destruction by gastrointestinal contents or hepatic firstpass inactivation of drug[4]. Mucoadhesive drug delivery systems are delivery systems, which utilize the property of bioadhesion of certain polymers, which become adhesive on hydration and hence can be used for targeting of drug to particular region of the body[5]. The MS is a leukotriene receptor antagonist used for the maintenance treatment of asthma, chronic asthma attacks and to relive symptoms of seasonal allergies[6]. The main drawback of conventional PEER REVIEW ABSTRACT